Fig. 6.

Major structural interactions of known PARP inhibitors with the NAD+ binding pocket. Crystal structures of known PARP inhibitors demonstrate how various small molecules can exploit different features in the nicotinamide and adenosine subsites in the NAD+ binding pocket